Reference 5

Level I Good quality evidence Systematic review of RCTs with
consistent findings
High quality individual RCT
Level II Limited quality patient
orientated evidence
Systematic review of lower quality
studies or studies with inconsistent
findings
Low quality clinical trial
Cohort studies
Case-control studies
Level III Other Consensus guidelines, extrapolations
from bench research, usual practice,
opinion, disease-oriented evidence
(intermediate or physiologic outcomes
only), or case series

[5] Beclomethasone, topical, aqueous nasal spray (drug-drug interaction with protease inhibitors): Foisy MM, Yakiwchuk EM, Chiu I, Singh AE. Adrenal suppression and Cushing's syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature. HIV Med. 2008 Jul;9(6):389-96. https://www.ncbi.nlm.nih.gov/pubmed/18459946

Beclomethasone, topical, aqueous nasal spray (drug-drug interaction with protease inhibitors): University of Liverpool. HIV drug interaction database. https://www.hiv-druginteractions.org/

Beclomethasone, topical, aqueous nasal spray (drug-drug interaction with protease inhibitors): Frankel JK, Packer CD. Cushing's syndrome due to antiretroviral-budesonide interaction. Ann Pharmacother. 2011 Jun;45(6):823-4. https://www.ncbi.nlm.nih.gov/pubmed/21558486

Beclomethasone, topical, aqueous nasal spray (drug-drug interaction with protease inhibitors): Yoganathan K, David L, Williams C, Jones K. Cushing's syndrome with adrenal suppression induced by inhaled budesonide due to a ritonavir drug interaction in a woman with HIV infection. Int J STD AIDS. 2012 Jul;23(7):520-1. https://www.ncbi.nlm.nih.gov/pubmed/22844010